Hypercholesterolemia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 153 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hypercholesterolemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hypercholesterolemia - Pipeline Review, H2 2014', provides an overview of the Hypercholesterolemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hypercholesterolemia Overview 11
Therapeutics Development 12
Pipeline Products for Hypercholesterolemia - Overview 12
Pipeline Products for Hypercholesterolemia - Comparative Analysis 13
Hypercholesterolemia - Therapeutics under Development by Companies 14
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 17
Hypercholesterolemia - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Hypercholesterolemia - Products under Development by Companies 22
Hypercholesterolemia - Products under Investigation by Universities/Institutes 24
Hypercholesterolemia - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Johnson & Johnson 26
Amgen Inc. 27
Eli Lilly and Company 28
Merck & Co., Inc. 29
Pfizer Inc. 30
Santaris Pharma A/S 31
SoluBest Ltd. 32
Alnylam Pharmaceuticals, Inc. 33
Regeneron Pharmaceuticals, Inc. 34
CrystalGenomics, Inc. 35
Catabasis Pharmaceuticals, Inc. 36
Planet Biotechnology Inc. 37
Zhejiang Hisun Pharmaceutical Co., Ltd. 38
Esperion Therapeutics, Inc. 39
Progenra, Inc. 40
Serometrix, LLC 41
Hanmi Pharmaceuticals, Co. Ltd. 42
AtheroNova Inc. 43
Immune Response BioPharma, Inc. 44
Agilvax, Inc. 45
Michigan Life Therapeutics, LLC 46
LondonPharma Ltd 47
Dybly AG 48
Hypercholesterolemia - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Target 51
Assessment by Mechanism of Action 54
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
anacetrapib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
alirocumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
(aspirin + lisinopril + lovastatin) - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
HCP-1306 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ETC-1002 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule to Inhibit LDL-C for Hypercholesterolemia - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
evolocumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
bococizumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
LY-3015014 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
HS-25 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
CAT-2003 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AEM-28 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MGL-3196 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ALN-PCS02 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
BMS-962476 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
AHRO-001 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
simvastatin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
fluvastatin sodium - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
pravastatin sodium - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PF-06678552 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
fenofibrate - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ALN-PCSsc - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
1D05-Fab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
IR-1002 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
gemcabene calcium - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
aplexone - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
DYB-186 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
EP-80317 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Vaccine for Metabolic Disorders - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Synthetic Peptide for Hypercholesterolemia - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
SX-PCK9 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecules to Inhibit IDOL for Hypercholesterolemia - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Drugs for Hypercholesterolemia - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Hypercholesterolemia - Recent Pipeline Updates 114
Hypercholesterolemia - Dormant Projects 139
Hypercholesterolemia - Discontinued Products 140
Hypercholesterolemia - Product Development Milestones 141
Featured News & Press Releases 141
Sep 02, 2014: Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency 141
Aug 31, 2014: Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 142
Aug 28, 2014: Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 144
Aug 28, 2014: Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 145
Aug 25, 2014: Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 146
Aug 12, 2014: Esperion Therapeutics Provides ETC-1002 Development Program Update 147
Jul 30, 2014: Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 147
Jul 30, 2014: Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 148
Jul 24, 2014: Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension 149
Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects 150
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 153
Disclaimer 153

List of Tables
Number of Products under Development for Hypercholesterolemia, H2 2014 12
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Hypercholesterolemia - Pipeline by Bristol-Myers Squibb Company, H2 2014 25
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2014 26
Hypercholesterolemia - Pipeline by Amgen Inc., H2 2014 27
Hypercholesterolemia - Pipeline by Eli Lilly and Company, H2 2014 28
Hypercholesterolemia - Pipeline by Merck & Co., Inc., H2 2014 29
Hypercholesterolemia - Pipeline by Pfizer Inc., H2 2014 30
Hypercholesterolemia - Pipeline by Santaris Pharma A/S, H2 2014 31
Hypercholesterolemia - Pipeline by SoluBest Ltd., H2 2014 32
Hypercholesterolemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 33
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 34
Hypercholesterolemia - Pipeline by CrystalGenomics, Inc., H2 2014 35
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 36
Hypercholesterolemia - Pipeline by Planet Biotechnology Inc., H2 2014 37
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2014 38
Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H2 2014 39
Hypercholesterolemia - Pipeline by Progenra, Inc., H2 2014 40
Hypercholesterolemia - Pipeline by Serometrix, LLC, H2 2014 41
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 42
Hypercholesterolemia - Pipeline by AtheroNova Inc., H2 2014 43
Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H2 2014 44
Hypercholesterolemia - Pipeline by Agilvax, Inc., H2 2014 45
Hypercholesterolemia - Pipeline by Michigan Life Therapeutics, LLC, H2 2014 46
Hypercholesterolemia - Pipeline by LondonPharma Ltd, H2 2014 47
Hypercholesterolemia - Pipeline by Dybly AG, H2 2014 48
Assessment by Monotherapy Products, H2 2014 49
Assessment by Combination Products, H2 2014 50
Number of Products by Stage and Target, H2 2014 53
Number of Products by Stage and Mechanism of Action, H2 2014 56
Number of Products by Stage and Route of Administration, H2 2014 58
Number of Products by Stage and Molecule Type, H2 2014 60
Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H2 2014 114
Hypercholesterolemia - Dormant Projects, H2 2014 139
Hypercholesterolemia - Discontinued Products, H2 2014 140